Sign up for the PlasticsToday NewsFeed newsletter.
Sponsored By
Norbert Sparrow
June 14, 2023
2 Min Read
mkurtbas/iStock via Getty Images
Medtech contract manufacturing group Arterex has signed an agreement to acquire NextPhase Medical Devices LLC, a US company specializing in electromechanical, active implantable, and single-use devices. The deal doubles the size of the group and creates a “top-tier global medical device contract manufacturer with 70% of revenues generated in the United States,” said Arterex.
The terms of the transaction, which is subject to customary approvals, were not disclosed.
NextPhase is a Class II and III medical device contract manufacturer with facilities in Waldwick, NJ; Rochester, NH; Mansfield, MA; and Tijuana, Mexico. It provides design and engineering, manufacturing and assembly, quality and regulatory, and supply chain and logistics management services, with a focus on low- to medium-volume complex medical devices.
Arterex was formed in 2022 by bringing together four complementary US and EU companies with the goal of building a comprehensive global contract manufacturing portfolio for medical device OEMs. The venture was engineered by Investindustrial, a European group with a €13 billion stockpile to support mid-market companies.
The companies that make up Arterex are as follows:
Formula Plastics, an injection molder with a full range of assembly and secondary operations at plants in California and Mexico;
Kabo, a supplier of medical bags located in Italy and Egypt;
Luc & Bel, an Italian company that designs and manufactures custom components for infusion, hemodialysis, cardiac surgery, and transfusion;
ModenPlast, a medical-grade PVC extruder and molder located in the Modena region, the heart of Italy’s medtech cluster.
With the addition of NextPhase, the Arterex group comprises seven end-to-end manufacturing facilities across North America, Europe, and North Africa and supports a broad range of manufacturing capabilities.
The newest acquisition is “transformational,” according to Arterex Executive Chairman Charles Stroupe, because of the complementary manufacturing and assembly capabilities it brings to the Arterex platform. “With the resulting capability diversification, this transaction will allow us to create significant synergies and enable us to better service our combined core blue-chip medical OEM customer base and regional specialty customers. Our combined platform will also have substantial production capabilities with a significantly diverse customer base across North America and Europe, well-positioned to continue our global growth strategy,” said Stroupe in a prepared statement.
About the Author(s)
You May Also Like
